electroCore (ECOR) announced the completion of the merger with NeuroMetrix (NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix’s Quell Fibromyalgia Solution expands electroCore’s portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach – particularly within the VA Hospital System – and is expected to meaningfully increase its addressable market for the treatment of chronic pain and wellness conditions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ECOR:
- electroCore’s Truvaga works with Apple Health app
- electroCore announces new data presented on nVNS
- electroCore extends VA contract for five years
- Electrocore’s Promising Growth and Strategic Positioning Earns Buy Rating from Analyst Vendetti
- ElectroCore’s Earnings Call: Robust Growth Amid Challenges